key: cord-1039292-8ce89oex
authors: Francis, Magen E.; Goncin, Una; Kroeker, Andrea; Swan, Cynthia; Ralph, Robyn; Lu, Yao; Etzioni, Athema L.; Falzarano, Darryl; Gerdts, Volker; Machtaler, Steven; Kindrachuk, Jason; Kelvin, Alyson A.
title: SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney
date: 2021-04-08
journal: bioRxiv
DOI: 10.1101/2021.04.07.438843
sha: 173b74193ddd59c8661a066a50863e894c7a8418
doc_id: 1039292
cord_uid: 8ce89oex

COVID-19 (coronavirus disease 2019) caused SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection is a disease affecting several organ systems. A model that captures all clinical symptoms of COVID-19 as well as long-haulers disease is needed. We investigated the host responses associated with infection in several major organ systems including the respiratory tract, the heart, and the kidneys after SARS-CoV-2 infection in Syrian hamsters. We found significant increases in inflammatory cytokines (IL-6, IL-1beta, and TNF) and type II interferons whereas type I interferons were inhibited. Examination of extrapulmonary tissue indicated inflammation in the kidney, liver, and heart which also lacked type I interferon upregulation. Histologically, the heart had evidence of mycarditis and microthrombi while the kidney had tubular inflammation. These results give insight into the multiorgan disease experienced by people with COVID-19 and possibly the prolonged disease in people with post-acute sequelae of SARS-CoV-2 (PASC).

The SARS-CoV-2 (severe acute respiratory coronavirus 2) which causes COVID-19 (coronavirus 2019) emerged in late 2019 with subsequent massive public health and economic impacts 1,2 . SARS-CoV-2 is a positive-sense, single-stranded RNA virus of family Coronoviridae, genus Betacoronavirus, and since its emergence has led to 124 million confirmed cases and 2.7 million deaths worldwide 3,4 .

Although coronavirus infections in humans were previously thought to only cause mild, cold-like symptoms, the more recent coronaviruses to emerge, SARS-CoV-1 and MERS-CoV (Middle East Respiratory Syndrome coronavirus), are associated with a wide array of respiratory and non-respiratory symptoms 5,6 , ranging from mild to severe, leading to organ failure and death 7 . Asymptomatic cases have also been reported 8 . Given the burden on public health, as well as the range of disease severity, developing animal models in order to study SARS-CoV-2 pathogenesis and identify countermeasures is of high importance. In vivo assessment of host response to viral infection is essential to identify host factors regulating severe disease as well as biomarkers that may help inform patient supportive care measures.

Assessment of host response to SARS-CoV-2 has led to valuable insight into disease progression and possible immune mechanisms leading to severe disease. It has now been widely shown that severe cases of COVID-19 in humans are often accompanied by increased expression of inflammatory genes,

including Interleukin-6 (IL-6), Interleukin-1 beta (IL-1beta) and Tumour Necrosis Factor (TNF) [11] [12] [13] .

Prior to SARS-CoV-2, it was known that coronaviruses were capable of regulating the type I interferon response 14, 15 . Several studies have found that type I interferon responses are significantly blunted during SARS-CoV-2 infection suggesting this may also contribute to poor COVID-19 outcomes 16, 17 . These clinical data suggest potential markers of pathogenesis for further experimental investigations.

Syrian hamsters were one of a handful of animal species identified early during the pandemic to be productively infected with SARS-CoV-2 and of potential use for preclinical development and in vivo analysis 18 . Hamsters were originally determined to be susceptible to SARS-CoV-1 19 and since have been shown to be an ideal model for SARS-CoV-2 20 . Hamsters are able to support SARS-CoV-2 replication within the lower respiratory tract [20] [21] [22] with similar infection and disease dynamics to humans 23 , in contrast to ferrets and mice 24 . Further, hamsters mount an effective antibody response and have been utilized for both COVID-19 vaccine and treatment studies 21, 22, 25 . As with other non-traditional animal models, there is a lack of hamster-specific biological reagents for characterizing immune responses and the mechanisms of pathogenesis 26 .

Here, we investigated the immune response and pathogenesis of SARS-CoV-2 infection in hamsters to determine disease mechanisms and the involvement of specific organs such as the lungs, heart, and kidney since COVID-19 is a multisystem disease. SARS-CoV-2 inoculated Syrian hamsters were sampled over a 

the respiratory tract, and viral RNA in non-respiratory tissues.

Syrian hamsters are susceptible to infection with SARS-CoV-2 suggesting they may be valuable for the investigation of immunopathology and mechanisms of disease 22 . Hamsters aged 6-8 weeks were inoculated intranasally with SARS-CoV-2 at 10 5 TCID50. The animals were monitored for temperature and weight throughout the course of the infection. As typical during viral infection in small animals, hamsters began showing a decrease in temperature by day 1 post inoculation (pi) ( Figure 1A ) which returned to baseline between day 3 and 7 ( Figure 1B) . Inoculated hamsters began losing weight on day 2 pi, with weights being significantly different from baseline on days 3 to 7. Weight loss was most severe on day 6 pi where the average body weight of the inoculated animals was 88.26% of original weight ( Figure 1C) . After day 6, there was a steady increase in weight over the remaining time course on average recovering to baseline by day 12. Individual animals showed two different trajectories of weight loss: mild (~4% weight loss) and severe (>15% weight loss) ( Figure 1D) . No animals lost ≥20% of original weight or reached endpoint criteria during the study.

COVID-19 affects several organ systems in humans including the heart, kidneys, liver, spleen and large intestine 31,32 . Therefore, we were interested in determining the tropism of the virus and associated immunopathology throughout the body of infected hamsters to gain insight into disease.

Animals were removed from the study on days 0, 2, 5, 8, 12 and 15 pi to assess tissue-specific responses for necropsy and analysis of the immunopathology. Blood, nasal washes and tissues (respiratory and non-respiratory) were collected. Viral tropism was assessed by qRT-PCR for the SARS-CoV-2 envelope gene (E) and virus titration with TCID50 assays (Figure 2 ). E gene expression analysis is represented by brown circles on the graphs. Analysis of the respiratory tract revealed vRNA present in the nasal turbinates, trachea, and all four tested lung lobes (right cranial, right middle, right caudal, and accessory) on days 2, 5 and 8 pi. Viral RNA was still detected in the right middle lung lobe and the accessory lung lobe of one animal on day 12 pi. Live viral titer analysis, represented by the grey circles, indicated that infectious virus was present in the nasal turbinates on days 2 (7.5 TCID50/mL (Log10)) and 5 (6 TCID50/mL (Log10)) pi. Infectious virus peaked in the lungs on day 2, at ~9 TCID50/mL (Log10) in the right middle lung and was present until day 5. The trachea had the lowest virus levels of all the respiratory tissue which was only present on day 2 (~3 TCID50/mL (Log10)). vRNA was also detected in non-respiratory tissues including the heart, kidney, large intestine, and the mediastinal lymph node at low to moderate levels. The mediastinal lymph node had the highest level of vRNA, ~5 TCID50 (Log10) and was the only non-respiratory tissue to be positive for infectious virus.

To determine if virus resolution was due to elicitation of neutralizing antibodies, we next quantified the neutralizing antibody titers in infected hamsters throughout the time course ( Figure 3A) .

Plasma was isolated from blood collected at necropsy to be used for neutralization assays at 100

TCID50 per reaction of SARS-CoV-2. Neutralizing antibodies were detected as early as day 8 pi, at an endpoint titer of approximately 63 (geometric mean). This increased to a geometric mean of 160 on day 12 and peaked on day 15 at a geometric mean of 587. These observations suggested that hamsters are able to elicit high titers of neutralizing antibodies after SARS-CoV-2 infection. Nasal washes were collected throughout the study to determine viral shedding from the upper respiratory tract. vRNA was detected in the nasal washes up to 12 days after inoculation with live virus observed on days 2 and 5, peaking at day 2 at just over 6 TCID50/mL (Log10). We compared the live viral titer found in the nasal washes of all animals on day 5 to their respective weight loss on that day ( Figure 3B ). We found a Pearson correlation of -0.68 such that as the viral titer in the nasal washes increased, animals had increased likelihood of more severe weight loss (p-value= 0.00242).

Pneumonia and lung pathology are often the defining feature of respiratory viral infection, resulting in significant morbidity and mortality. To determine the extent of damage to the lungs in SARS-CoV-2 infected hamsters, and the ability of hamsters to recapitulate the severe respiratory involvement in human COVID-19 patients, we examined disease pathogenesis within the left lung of hamsters throughout course of infection (Figure 4) . Microscopic analysis of H&E staining indicated an increase in damage in the lung over the course of the infection, with the most severe pathology noted on day 8 pi which partially resolved by day 15 (Figure 4A) To quantify inflammation and inflammatory cell infiltration as well as edema in the lung, the weights of the lungs at necropsy were analyzed. The entire lung was weighed at necroscopy and a ratio to the animal's body weight was calculated and then expressed as a percentage ( Figure 4C ). On day 0 and 2 pi, the lung was less than one percent of hamster body weight. This increased to a significant peak on day 5 at just under 4 percent of body weight on average. Lung weight decreased to above 1 percent and remained statistically significant from baseline throughout the remaining time course.

with blunted type I interferon signaling in the respiratory tract.

Since the human data investigated systemic cytokine levels in the blood, we were interested in determining the immune responses at the site of infection as well as other affected organs. We Human clinical reports have indicated that SARS-CoV-2 infection leads to a dysregulation of the interferon response 16 .We investigated the type I and II IFN responses by evaluating the expression of IFN-beta, STAT2, and IRF1 for the type I response and IFN-gamma, IRF2, STAT1, and CXCL10

for the type II response (Figure 5 ). IFN-beta was significantly downregulated in both the nasal turbinates and right cranial lung with the greatest inhibition on day 2. Downstream regulators of the type I IFN response were also decreased, including STAT2 and IRF1 which reached maximum inhibition later in the time course. We also examined the type II IFN response, as well as genes whose corresponding proteins act in both IFN pathways. IFN-gamma, the type II IFN, showed upregulation in the nasal turbinates, and most prominently in the lung (Figure 5 ). In both tissues there was an increase to a peak followed by resolution by day 15 pi. Nasal turbinate levels of IFN-gamma peaked on day 8 at a fold-change of 12, while levels in the lung peaked on day 5 at a fold-change of 17. In the respiratory tissues, type I IFN antagonist IRF2 showed significant increases, peaking on day 8 in the nasal turbinate and day 2 in the right cranial lung, at a fold-changes of 24 and 25, respectively. General IFN response molecules showed significant increases as well. STAT1 showed strong upregulation in both tissues on days 2 and 5, while CXCL10 peaked at day 2 in the nasal turbinates at a fold-change of close to 70. In the lung, CXCL10 peaked on day 8 at a fold-change of 30 but did not resolve back down to baseline and remained significantly increased relative to naïve animals on days 12 and 15 pi.

From this data, it appears that while the type II IFN response remains intact, hamsters inoculated with SARS-CoV-2 show a dysregulated type I IFN response in respiratory tissues.

Additionally, we also assessed innate and adaptive gene regulation. Overall, these genes were Table S1 . In contrast, these transcripts reached apex between days 2 and 5, but at a lower fold-change compared to the lung. In both the nasal turbinates and in the lung several inflammatory cytokines remained elevated compared to baseline until day 12 pi. Taken together, the sites of infection showed a clear increase in inflammatory markers, especially IL-6 in the nasal turbinates and TNF in the lung.

node, and spleen as well as eosinophil signatures in the large intestine.

Immune markers of inflammation, adaptive immunity, and the antiviral responses were also assessed in non-respiratory tissues alongside histopathology of the tissues. We investigated the mediastinal lymph node, heart, kidney, spleen, liver and large intestine for regulation of immune targets categorized as above by type I IFN, type II/General IFN Response, and Innate/Adaptive Mediators ( Figure 6 ) as well as for immunopathology ( Figure S1 and Figure 7 ). If initial assessment of histopathology suggested the involvement of specific immune mechanisms ( Figure S1 ), high resolution scanning was performed to acquire a greater depth of information (Figure 7) . Mediastinal lymph nodes were not able to be recovered on day 15. Corresponding significances for the gene expression can be found in Table S2 .

The type I and type II IFN responses in all the extrapulmonary organs except the liver had similar regulation profiles as those of the lungs and nasal turbinates (Figure 6 ). Gene regulation was characterized by decreased type I responses and increases in type II responses. STAT2 was significantly decreased in the mediastinal lymph node, kidney, spleen, and large intestine. The heart had significant and sustained decreases in IRF-1 while the large intestine had decreases in IFN-beta ( Figure 6) . Conversely, marked increases in IFN-gamma was observed in the mediastinal lymph node and kidney and to a lower extent in the heart and spleen. CXCL10, the T cell chemoattractant, was increased to high levels in the spleen, liver, and mediastinal lymph node where the regulation was biphasic in the lymph node ( Figure 6 ).

Regulation of the innate/adaptive mediator genes in the spleen and lymph node was seen for all immune targets examined with the exception of TGF-beta which was not effectively regulated.

Specifically, significant regulation of IL-2, IL-21, IL-10, IL-4, IL-5, IL-13, and IL-12 was noted in these secondary immune organs. The regulation of the innate/adaptive immune mediators was particularly interesting in the heart where IL-2, IL-10, IL-4, and IL-5 were increased 100 times over baseline. The highest upregulation of inflammatory cytokines was detected in the heart followed by the kidney, liver, and mediastinal lymph node. In the heart, IL-12 was significantly increased early and, along with TNF, remained elevated at day 15 pi. Il-6 and IL-1beta were also transiently induced in the heart tissue on days 5 and 8 ( Figure 6 ). Significant changes in the heart were observed by histological analysis (Figure S1 ). High-resolution imaging found evidence of microthrombi ( Figure   7A , white arrows) as well as myocarditis ( Figure 7B , white arrows) in the heart. IL-1beta and TNF were upregulated early in the kidney but decreased by day 8 to 12 pi (Figure 6 ) which coincided with infiltration of inflammatory cells into the kidney and possible acute kidney injury or tubular injury (indicated by the white arrows, Figure 7C ). IL-6 expression was sustained in the liver where IL-1beta

was also increased at late time points. The mediastinal lymph node had a biphasic increase in IL-12 with transient increases in IL-6 and TNF to fold levels of 12, 8 and 11, respectively. The large intestine had significant regulation of IL-5 with infiltration of eosinophils ( Figure 7D ), but minimal regulation of any other innate/adaptive mediators.

To accompany analysis of the extra-pulmonary organs, we analyzed blood chemistries in the animals over the time course to assess organ dysfunction ( Figure S3 ). We analyzed glucose, albumin, alkaline phosphatase, alanine transferase, blood urea nitrogen, total bilirubin and total protein as a signs of liver function 33 . Calcium, potassium, albumin, amylase, blood urea nitrogen, and total protein were analyzed to assess the kidney 33 . Gastrointestinal health was evaluated through sodium, potassium, and alkaline phosphatase 33 . Cardiac function was measured using sodium, Alkaline phosphatase (gastrointestinal marker) was high on days 5 and 8 at 3u/L and alanine transferase (cardiac marker) was increased in infected hamsters relative to non-infected hamsters on days 2, 8 and 12 at 75-100 U/L. Lastly, globulin peaked on day 2 at 0.6 g/dL and decreased relatively linearly over the time course. Taken together, blood analysis indicates some dysregulation in extrapulmonary organs, as well as antigenic stimulation in response to SARS-CoV-2.

Originally SARS-CoV-2 infection was thought to mainly cause respiratory disease, but it is now clear that COVID-19 is a disease of many faces affecting several organ systems 31,32 . To Investigation of the extra-pulmonary organs also found a similar profile for type I and II IFN signaling; however, tissue-specific immune regulation was also identified. Specifically, significant expression of innate and adaptive mediators was identified in the heart and spleen. Since antiviral treatment during SARS-CoV-2 infection is only effective during a short window, 34 severe COVID-19 is thought to be a consequence of a dysregulated immune response 35 . Understanding immune pathogenesis is essential for identifying therapeutic targets and treating acute non-respiratory symptoms associated with COVID-19 including heart palpitations or migraines and longer-lasting To this end, we identified the upregulation of key inflammatory genes, such as IL-6 and TNF in the lungs and nasal turbinates confirming previous immune modeling in hamsters 38, 43 . These findings are important as these inflammatory markers have been shown to be predictors of severe disease via assessment of blood in humans 44-48 . More in-depth analysis of the host response to SARS-CoV-2 in the respiratory tissues of hamsters has been done using transcriptome sequencing analysis 49,50 . Hoagland and colleagues researchers assessed the lungs of SARS-CoV-2 infected hamsters for host immune gene regulation and found a prominent upregulation of IL-6, TNF, and IL-1beta 49 consistent with our PCR results. In another study single cell sequencing analysis revealed a prominent T cell response including upregulation of IFN-gamma and IL-2 50 , two markers we also noted to be highly expressed in the lungs. Importantly, the qRT-PCR analysis we reported in our present study is in agreement with these other studies thereby validating the use of qRT-PCR as a method to quickly assess the effectiveness of vaccines and therapeutics being evaluated in the hamster SARS-CoV-2 model. Our qRT-PCR profiles provide targeted biomarkers that can easily be employed.

The antiviral response is essential for the initial control of a virus by active destruction of viral replication and immune stimulation to limit the spread to other cells. 

Blood collected at necropsy was centrifuged to yield plasma. Blood biochemistry analyses were performed on 100 µL of plasma using the VetScan VS2 instrument (Abaxis Veterinary Diagnostics). Sample was loaded into the VetScan ® Comprehensive Diagnostic Profile Rotor.

The rotor was loaded in the VetScan VS2 Analyzer and analyzed as plasma samples from male hamsters. Results were analyzed in Prism 9.

The tissues collected for histopathology were submersed in formalin for at least 7 days within the 

Unpaired, unequal variance, two-tail Student's t-test or one-way ANOVAs were conducted using GraphPad Prism8 (San Diego, USA). A p value of ≤ 0.05 was considered statistically significant.

The data that support the findings of this study are available from the corresponding author upon reasonable request. IL-4, IL-5, IL-13, IL-12, IL-1beta, IL-6, TNF) using primers specific to hamster genes ( Table 1) .

Fold-change was calculated via Ct against baseline (Day 0) with BACT as the housekeeping gene. At least three animals were analyzed for each timepoint. 

SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes

WHO. Information for Pediatric Healthcare Providers

The COVID-19 Pandemic and the $16 Trillion Virus

IMF estimates global Covid cost at $28tn in lost output

Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools

COVID-19 infection: the perspectives on immune responses

Immune Response, Inflammation, and the Clinical Spectrum of COVID-19

Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response

Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

The type I interferon response in COVID-19: implications for treatment

Animal models for COVID-19

Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters

Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19

Infection and Rapid Transmission of SARS-CoV-2 in Ferrets

Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv

Dysregulation of Immune Response in Patients With Coronavirus

Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies

Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection

STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters

Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques

Respiratory follow-up of patients with COVID-19 pneumonia

COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy

Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series

Regulation of type I interferon responses

An immune-based biomarker signature is associated with mortality in COVID-19 patients

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Activation and evasion of type I interferon responses by SARS-CoV-2

Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV

Evasion of Type I Interferon by SARS-CoV-2

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling

Cell-Type-Specific Immune Dysregulation in Severely Ill

Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19

The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

The ORF8 protein of SARS-CoV-2 induced endoplasmic reticulum stress and mediated immune evasion by antagonizing production of interferon beta

Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling

Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus

Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

SARS-CoV-2 is sensitive to type I interferon pretreatment. bioRxiv

Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells

Interferon-alpha2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

Macrophage cytokines: involvement in immunity and infectious diseases

Contributions of Eosinophils to Human Health and Disease

Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

First case of COVID-19 complicated with fulminant myocarditis: a case report and insights

SARS-CoV-2 inflames the heart. The importance of awareness of myocardial injury in COVID-19 patients

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

COVID-19 Can Wreck Your Heart

Role of Monocytes in Heart Failure and Atrial Fibrillation

T-cell recruitment to the heart: friendly guests or unwelcome visitors?

Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure

Myocarditis in COVID-19 patients: current problems

Acute eosinophilic myocarditis mimicking myocardial infarction

Molecular biology and pathogenesis of viral myocarditis

Viral myocarditis. A review

The Clinicopathological Profile of Eosinophilic Myocarditis

Fatal Eosinophilic Myocarditis in a Healthy 17-Year-Old Male with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2c)

Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy

Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past

T cell responses in patients with COVID-19

The main function of IL-2 is to promote the development of T regulatory cells

Coordinate regulation of the IL-4, IL-13, and IL-5 cytokine cluster in Th2 clones revealed by allelic expression patterns

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing

CD4 memory T cells: what are they and what can they do?

IL-21 and T follicular helper cells

SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes. medRxiv

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19

Structure and function of the immune system in the spleen

The multifaceted biology of plasmacytoid dendritic cells

The spleen in local and systemic regulation of immunity

Tissue-resident macrophages

Innate lymphoid cells in tissue homeostasis and diseases

Interleukin-5 and IL-5 receptor in health and diseases

Type 1/Type 2 immunity in infectious diseases

Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus

Functions of tissue-resident eosinophils

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Persistence of intestinal SARS-CoV-2 infection in patients with COVID-19 leads to re-admission after pneumonia resolved

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study

Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19

Acknowledgments We greatly acknowledge the review of this manuscript by Dr. Kristen Kindrachuk and the assistance of Swarali Kulkarni and Dr. Vinoth Manoharan. Funding A. Kelvin is funded by the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding initiative the Canadian Institutes of Health Research (CIHR) (grant numbers OV5-170349, VRI-172779, and OV2 -170357) and Atlantic Genome/Genome Canada, Scotiabank COVID-19 IMPACT grant, and the Nova Scotia COVID-19

Falzarano is funded by the Canadian Institutes of Health Research (CIHR), grant number OV5

Kindrachuk is funded by a Tier 2 Canada Research Chair in the Molecular Pathogenesis of Emerging and Re-Emerging Viruses provided by the Canadian Institutes of Health Research (Grant no. 950-231498)

VIDO receives operational funding from the Canada Foundation for Innovation through the Major Science Initiatives Fund and by Government of Saskatchewan through Innovation Saskatchewan and the Ministry of Agriculture